Feasibility Study of the FARAFLEX Mapping and PFA System

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 250 participants.

Also called NCT06510556

  • Study
  • In this atlas

Overview

Design
Interventional study; non-randomized; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 250 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06510556
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Belgium, Croatia, Czechia, Italy (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06510556. Non-randomized; no masking; primary purpose treatment. Start 2025-02-17 (actual); primary completion 2027-02-15 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Feasibility Study of the FARAFLEX Mapping and PFA System
Acronym
ELEVATE-PF
Condition
Persistent Atrial Fibrillation
Condition
Paroxysmal AF
Intervention (Device)
FARAFLEX Ablation Treatment
Intervention (Device)
ELEVATE-COR Sub-study
Lead sponsor
Boston Scientific Corporation (class: industry)

Record details

Record id
cardio:ct-nct06510556
Content hash
e3a859610ff457121bbb4544d0fb4b485e86cf65eb20d086334cd89094754c44